State of Alaska Department of Revenue’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.66M | Sell |
9,852
-128
| -1% | -$19K | 0.02% | 778 |
|
|
2026
Q1 | $1.31M | Buy |
9,980
+15
| +0.2% | +$1.99K | 0.01% | 933 |
|
|
2025
Q4 | $1.41M | Sell |
9,965
-645
| -6% | -$93.4K | 0.02% | 888 |
|
|
2025
Q3 | $1.49M | Sell |
10,610
-505
| -5% | -$68.4K | 0.02% | 864 |
|
|
2025
Q2 | $1.4M | Sell |
11,115
-565
| -5% | -$64.8K | 0.01% | 874 |
|
|
2025
Q1 | $1.29M | Buy |
11,680
+145
| +1% | +$18.4K | 0.01% | 881 |
|
|
2024
Q4 | $1.57M | Sell |
11,535
-200
| -2% | -$24.7K | 0.02% | 825 |
|
|
2024
Q3 | $1.35M | Buy |
11,735
+795
| +7% | +$109K | 0.01% | 910 |
|
|
2024
Q2 | $1.51M | Buy |
10,940
+145
| +1% | +$19.9K | 0.02% | 793 |
|
|
2024
Q1 | $1.49M | Buy |
10,795
+185
| +2% | +$25.3K | 0.02% | 831 |
|
|
2023
Q4 | $1.4M | Sell |
10,610
-995
| -9% | -$115K | 0.02% | 837 |
|
|
2023
Q3 | $1.3M | Sell |
11,605
-490
| -4% | -$51.6K | 0.02% | 816 |
|
|
2023
Q2 | $1.14M | Sell |
12,095
-1,214
| -9% | -$119K | 0.01% | 906 |
|
|
2023
Q1 | $1.35M | Sell |
13,309
-147
| -1% | -$15.3K | 0.02% | 831 |
|
|
2022
Q4 | $1.61M | Buy |
13,456
+185
| +1% | +$21.7K | 0.02% | 730 |
|
|
2022
Q3 | $1.41M | Sell |
13,271
-460
| -3% | -$46.7K | 0.02% | 762 |
|
|
2022
Q2 | $1.34M | Buy |
13,731
+385
| +3% | +$35.5K | 0.02% | 803 |
|
|
2022
Q1 | $1.25M | Sell |
13,346
-385
| -3% | -$32.6K | 0.01% | 888 |
|
|
2021
Q4 | $1.17M | Sell |
13,731
-795
| -5% | -$73.1K | 0.01% | 1000 |
|
|
2021
Q3 | $1.39M | Sell |
14,526
-157
| -1% | -$14.8K | 0.01% | 900 |
|
|
2021
Q2 | $1.43M | Sell |
14,683
-45,517
| -76% | -$4.36M | 0.01% | 894 |
|
|
2021
Q1 | $5.85M | Buy |
60,200
+9,444
| +19% | +$990K | 0.06% | 341 |
|
|
2020
Q4 | $4.86M | Sell |
50,756
-8,184
| -14% | -$790K | 0.06% | 366 |
|
|
2020
Q3 | $5.67M | Buy |
58,940
+385
| +0.7% | +$44.5K | 0.07% | 315 |
|
|
2020
Q2 | $7.14M | Buy |
+58,555
| New | +$6.47M | 0.09% | 294 |
|
|
2019
Q3 | – | Sell |
-10,532
| Closed | -$889K | – | 1712 |
|
|
2019
Q2 | $889K | Buy |
10,532
+30
| +0.3% | +$2.46K | 0.01% | 796 |
|
|
2019
Q1 | $925K | Sell |
10,502
-493
| -4% | -$41.2K | 0.02% | 755 |
|
|
2018
Q4 | $785K | Buy |
10,995
+80
| +0.7% | +$7.66K | 0.02% | 752 |
|
|
2018
Q3 | $1.34M | Buy |
10,915
+115
| +1% | +$13K | 0.02% | 635 |
|
|
2018
Q2 | $1.06M | Buy |
10,800
+2,630
| +32% | +$235K | 0.02% | 686 |
|
|
2018
Q1 | $677K | Buy |
8,170
+1,770
| +28% | +$149K | 0.01% | 805 |
|
|
2017
Q4 | $496K | Buy |
+6,400
| New | +$437K | 0.01% | 807 |
|
Other funds holding NBIX
IC
State of Alaska Department of Revenue's NBIX Position: Q2 2026 in Review
State of Alaska Department of Revenue reduced its Neurocrine Biosciences (NBIX) stake by 1.3% in Q2 2026, selling an estimated $19K and leaving 9,852 shares worth $1.66M. The position accounts for 0.02% of the portfolio, ranked #778.
State of Alaska Department of Revenue first reported a position in NBIX in Q4 2017 and has held it in 32 quarters since. The position peaked at $7.14M in Q2 2020. 579 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- State of Alaska Department of Revenue held 9,852 shares of Neurocrine Biosciences worth $1.66M as of Q2 2026.
- State of Alaska Department of Revenue sold 128 Neurocrine Biosciences shares in Q2 2026, an estimated $19K.
- Neurocrine Biosciences made up 0.02% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #778 holding.
- State of Alaska Department of Revenue first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 32 quarters since.
- State of Alaska Department of Revenue's Neurocrine Biosciences position peaked at $7.14M in Q2 2020.
- 579 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.